2

Claims 1-7 (canceled)

Claim 8 (currently amended) A crystalline polymorph Form I of

(-) 4 [4 [4 [4 [[(2R-eis) -5 -(2,4 difluorophenyl)tetrahydro -5 -(1H-1,2,4 triazol -1 ylmethyl)furan -3 -yl]methoxy]phenyl] 1 piperazinyl]phenyl 2,4 dihydro 2 [-(S) -1 ethyl-2(S) -hydroxylpropyl] 3H -1,2,4 triazol -3 one
the compound represented by the formula I

and characterized by at least one of the following properties:

- a melting point range of about 164 to about 165°C wherein the melting point range is determined using USP Class Ia procedure;
- a specific rotation equal to  $[a]^{25}D = -29.4^{\circ}$  wherein the specific rotation is determined using a concentration of 10 mg/ml in methanol;
- the an X-ray powder diffraction pattern substantially similar to that presented in Figure 1;
- the <u>a</u> differential scanning calorimetry thermogram <u>substantially similar to that</u> presented in Figure 7; and <u>or</u>
- the a proton NMR spectrum substantially similar to that presented in Figure 10.

Claims 9 and 10 (canceled)

Claim 11 (previously presented) A pharmaceutical composition comprising an antifungally effective amount of the crystalline polymorph form I of claim 8 and a pharmaceutically acceptable carrier.

Claims 12 and 13 (canceled)

Amendment filed with RCE Patent Case: CD0787Q1

3

Claim 14 (previously presented) A method of treating and/or preventing fungal infections in a mammal which comprises administering to said mammal an anti-fungally effective amount of the crystalline polymorph form I of claim 8.

Claim 15 (new) A crystalline polymorph Form II of the compound represented by the formula I

and characterized by an X-ray powder diffraction pattern displaying d spacing peaks at 20.05 and 13.84 +/-0.04.

Claim 16 (new) The crystalline polymorph Form II of Claim 15 further characterized by an X-ray powder diffraction pattern substantially similar to that presented in Figure 2.

Claim 17 (new) A pharmaceutical composition comprising an anti-fungally effective amount of the crystalline polymorph Form II of Claim 15 and a pharmaceutically acceptable carrier.

Claim 18 (new) A method of treating and/or preventing fungal infections in a mammal which comprises administering to said mammal an anti-fungally effective amount of the crystalline polymorph Form II of Claim 15.

Claim 19 (new) A crystalline polymorph Form III of the compound represented by the formula I

4

and characterized by an X-ray powder diffraction pattern displaying d spacing peaks at 28.69, 14.45, 10.59, 7.27, 6.59, 4.14, 3.58, and 3.53 +/-0.04.

Claim 20 (new) The crystalline polymorph Form III of Claim 19 further characterized by an X-ray powder diffraction pattern substantially similar to that presented in Figure 3.

Claim 21 (new) A pharmaceutical composition comprising an anti-fungally effective amount of the crystalline polymorph Form III of Claim 19 and a pharmaceutically acceptable carrier.

Claim 22 (new) A method of treating and/or preventing fungal infections in a mammal which comprises administering to said mammal an anti-fungally effective amount of the crystalline polymorph Form III of Claim 19.